Sort by
Quarterly Activities/Appendix 4C Cash Flow Report
Notice of Annual General Meeting/Proxy Form
Radiopharm receives $8M advance on FY26 R&D tax incentive
Notification regarding unquoted securities - RAD
Change of Director's Interest Notices x 4
Notification of cessation of securities - RAD
Non-Compliance with Listing Rule 10.11
RAD Completes Meeting with US FDA for Development of RAD101
Notification of cessation of securities - RAD
Change of Director's Interest Notice (RC)
| Date | Headline |
|---|---|
30 Oct 2026 | Quarterly Activities/Appendix 4C Cash Flow Report |
27 Oct 2026 | Notice of Annual General Meeting/Proxy Form |
26 Oct 2026 | Radiopharm receives $8M advance on FY26 R&D tax incentive |
20 Oct 2026 | Notification regarding unquoted securities - RAD |
20 Oct 2026 | Change of Director's Interest Notices x 4 |
20 Oct 2026 | Notification of cessation of securities - RAD |
12 Oct 2026 | Non-Compliance with Listing Rule 10.11 |
5 Oct 2026 | RAD Completes Meeting with US FDA for Development of RAD101 |
1 Oct 2026 | Notification of cessation of securities - RAD |
1 Oct 2026 | Change of Director's Interest Notice (RC) |
